Publicaciones en colaboración con investigadores/as de Icahn School of Medicine at Mount Sinai (17)

2024

  1. Impact of OLD/Emphysema in LC Mortality Risk in Screening Programs: An Analysis of NLST and P-IELCAP

    Archivos de Bronconeumologia

  2. Metabolomic-Based Approaches for Endometrial Cancer Diagnosis and Prognosis: A Review

    Cancers, Vol. 16, Núm. 1

2023

  1. Epigenetic inactivation of the 5-methylcytosine RNA methyltransferase NSUN7 is associated with clinical outcome and therapeutic vulnerability in liver cancer

    Molecular Cancer, Vol. 22, Núm. 1

  2. Molecular portraits of patients with intrahepatic cholangiocarcinoma who diverge as rapid progressors or long survivors on chemotherapy

    Gut, Vol. 73, Núm. 3, pp. 496-508

2022

  1. Objective Response Predicts Survival in Advanced Hepatocellular Carcinoma Treated with Systemic Therapies

    Clinical Cancer Research, Vol. 28, Núm. 16, pp. 3443-3451

2021

  1. Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002–2020)

    Gastroenterology, Vol. 161, Núm. 3, pp. 879-898

  2. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

2020

  1. Copy-number alteration burden differentially impacts immune profiles and molecular features of hepatocellular carcinoma

    Clinical Cancer Research, Vol. 26, Núm. 23, pp. 6350-6361

  2. Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma

    Journal of Hepatology, Vol. 73, Núm. 2, pp. 315-327

2019

  1. Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials

    British Journal of Cancer, Vol. 121, Núm. 4, pp. 340-343

  2. Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial

    Gut, Vol. 68, Núm. 6, pp. 1065-1075

  3. New Drugs Effective in the Systemic Treatment of Hepatocellular Carcinoma

    Clinical Liver Disease, Vol. 14, Núm. 2, pp. 56-61

  4. Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival

    Journal of Hepatology, Vol. 70, Núm. 6, pp. 1262-1277

2018

  1. Molecular therapies and precision medicine for hepatocellular carcinoma

    Nature Reviews Clinical Oncology, Vol. 15, Núm. 10, pp. 599-616

2017

  1. Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity

    Journal of Hepatology, Vol. 66, Núm. 5, pp. 952-961

  2. Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC

    Journal of Hepatology, Vol. 66, Núm. 6, pp. 1166-1172

  3. Reply to: “mRECIST for systemic therapies: More evidence is required before recommendations could be made”

    Journal of Hepatology